medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2021, Number 3

<< Back

Rev Biomed 2021; 32 (3)

A single BNT162b2 dose protects against SARS-CoV-2: A case report of a family cluster of COVID-19

Morales-Contreras JA, Ruiz-Quiñonez JA, Roblero-Hernández A, Horemheb-Rubio G, Suarez-Mendez S

Language: English
References: 15
Page: 172-176
PDF size: 478.66 Kb.


ABSTRACT

Background. Coronavirus 2019 (COVID-19) disease is an infectious disease caused by the virus “Severe Acute Respiratory Syndrome Coronavirus 2” (SARS-CoV-2). This virus generated a pandemic in 2020 and has affected millions of people worldwide. Facing the need to prevent its contagion, the vaccine BNT162b2 was approved in December 2020 in Mexico and started being administered to healthcare workers.
Case presentation. We presented two healthcare workers vaccinated with one single dose of BNT162b2, who lives in a family nucleus with a high transmission rate of SARS-CoV-2. These healthcare workers, identified in the manuscript as patients E and F, were asymptomatic and their real-time RT-PCR test for SARS-CoV-2 resulted negative, while the rest of the family (patients A-D) were SARS-CoV-2 positive. The antibody titers IgG anti-spike of patient F (after the second dose; 1080 Au/mL) turned out greater than patient E (before the second dose; 37.1 Au/mL).
Discussion. To our knowledge, this is the first case report of the protective effect of a single BNT162b2 vaccine dose in the context of high transmission rates within a family nucleus. Despite changes induced by BNT162b2 in the antibody titers with single or double dose vaccination, a single dose of BNT162b2 showed to be sufficient for immunization of patients against COVID-19.


REFERENCES

  1. Adil MT, Rahman R, Whitelaw D, Jain V, Al-Taan O, Rashid F, et al. SARS-CoV-2 and the pandemic of COVID-19. Postgrad Med J. 2021;97(1144):110-116. https://doi.org/10.1136/postgradmedj-2020-138386

  2. 2019-nCoV outbreak is an emergency of international concern. World Health Organization. Available http://www.euro.who.int/en/health-topics/healthemergencies/ international-health-regulations/news/ news/2020/2/2019-ncov-outbreak-is-an-emergency-ofinternational- concern (accessed 27 May 2020).

  3. Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus Disease 2019-COVID-19. Clin Microbiol Rev. 2020;33(4):e00028-20. https://doi. org/10.1128/cmr.00028-20

  4. He Q, Mao Q, Zhang J, Bian L, Gao F, Wang J, et al. COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. Front Immunol. 2021;12:669339. https://doi. org/10.3389/fimmu.2021.669339

  5. US Food and Drug Administration. FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine [media release]. 11 Dec 2020. http://www.fda.gov.

  6. Vacunación COVID-19 dashboard. [Internet]. Secretaria de Salud. 2021 [cited 2021 April 21]. Available from: https://coronavirus.gob.mx/vacunacion-covid/.

  7. Lamb YN. BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021;81(4):495-501. https://doi. org/10.1007/s40265-021-01480-7

  8. Kalimuddin S, Tham CY, Qui M, de Alwis R, Sim JX, Lim JM, et al. Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset. Med (NY). 2021. https://doi.org/10.1016/j. medj.2021.04.003

  9. Favresse J, Bayart JL, Mullier F, Dogné JM, Closset M, Douxfils J. Early antibody response in healthcare professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). Clin Microbiol Infect. 2021; S1198-743X(21)00224-X. https://doi.org/10.1016/j. cmi.2021.05.004

  10. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. https://doi.org/10.1056/ NEJMoa2034577

  11. Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 induces SARS-CoV-2- neutralising antibodies and T cells in humans. medRxiv. 2020. https://doi.org/10.1038/s41586-021-03653-6

  12. Padoan A, Dall’Olmo L, Rocca FD, Barbaro F, Cosma C, Basso D, et al. Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. Clin Chim Acta. 2021;519:60-63. https://doi. org/10.1016/j.cca.2021.04.006

  13. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021;384(14):1372- 1374. https://doi.org/10.1056/NEJMc2101667

  14. Blain H, Tuaillon E, Gamon L, Pisoni A, Miot S, Picot MC, et al. Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose. JAMA. 2021;325(18):1898-1899. https://doi.org/10.1001/ jama.2021.6042

  15. Tauzin A, Nayrac M, Benlarbi M, Gong SY, Gasser R, Beaudoin-Bussières G, et al. A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses. bioRxiv: the preprint server for biology. 2021; 100290. https://doi.org/10.1101/2021.03.18.435972




2020     |     www.medigraphic.com